| Identification | Back Directory | [Name]
Baricitinib | [CAS]
1564241-79-7 | [Synonyms]
2H5]-Baricitinib
Baricitinib d5Q: What is
Baricitinib d5 Q: What is the CAS Number of
Baricitinib d5 Q: What is the storage condition of
Baricitinib d5 | [Molecular Formula]
C16H17N7O2S | [MOL File]
1564241-79-7.mol | [Molecular Weight]
371.42 |
| Hazard Information | Back Directory | [Uses]
Baricitinib-d5 is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively. | [References]
[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110
[2] Fridman JS, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010 May 1;184(9):5298-307. DOI:10.4049/jimmunol.0902819
[3] Jabbari A, et al. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine. 2015 Feb 26;2(4):351-5. DOI:10.1016/j.ebiom.2015.02.015
[4] Khan IM, et al. Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration resistance. Int J Obes (Lond). 2015 Nov;39(11):1607-18. DOI:10.1038/ijo.2015.104 |
|
|